Keynote Speakers

James W. Welsh, MD
Associate Professor
Radiation Oncology Department
The University of Texas MD Anderson Cancer Center
Email:
jwelsh@mdanderson.org


James W. Welsh, MD, is a tenured physician scientist at The University of Texas MD Anderson Cancer Center. Dr. Welsh started his oncology career in the Department of Molecular Oncology at Genentech Inc., at an exciting time when some of the first personalized target therapies were developed. While at Genentech he helped to discover and clone the Wnt-Induced secreted proteins (WISP) family of oncogenes. He later attended Dartmouth Medical School, and completed a residency in radiation oncology at the University of Arizona, where he helped develop a novel drug targeting c-Met kinase (MP-470). At MD Anderson, he is the head of the immune radiation program, which has a goal of using radiation to turn the tumor into an “in-situ” vaccine in order to prime T cells, turning radiation into a systemic therapy. Being able to both see patients and run a lab has provided insights on how to improve patient care which have resulted in the founding of three new companies Healios Oncology, MolecularMatch and OncoResponse.

Recent Publications

  1. Cheedella KS, Suzuki A, Xiao L, Hofstetter WL, Maru DM, Taketa T, Sudo K, Blum MA, Lin SH, Welsh J, Lee JH, Bhutani MS, Rice DC, Vaporciyan AA, Swisher SG, Ajani JA. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. Ann Oncol. In Press.
  2. Shirvani S, Smith B, Welsh J. Lobectomy, sublobar resection, and stereotactic radiation for early-stage non-small cell lung cancer in the elderly. JAMA. In Press.
  3. Li P, Wang X, Liu Z, Liu H, Xu T, Wang H, Gomez DR, Nguyen QN, Wang LE, Teng Y, Song Y, Komaki R, Welsh JW, Wei Q, Liao Z. Single Nucleotide Polymorphisms in CBLB, a Regulator of T-Cell Response, Predict Radiation Pneumonitis and Outcomes After Definitive Radiotherapy for Non-Small-Cell Lung Cancer. Clin Lung Cancer 17(4):253-262.e5, 7/2016. e-Pub 11/2015. PMID: 26732495.
  4. Schoenhals JE, Seyedin SN, Tang C, Cortez MA, Niknam S, Tsouko E, Chang JY, Hahn SM, Welsh JW. Preclinical Rationale and Clinical Considerations for Radiotherapy Plus Immunotherapy: Going Beyond Local Control. Cancer J 22(2):130-7, Mar-Apr, 3/2016. PMID: 27111909.
  5. 5. Cortez MA, Ivan C, Valdecanas D, Wang X, Peltier HJ, Ye Y, Araujo L, Carbone DP, Shilo K, Giri DK, Kelnar K, Martin D, Komaki R, Gomez DR, Krishnan S, Calin GA, Bader AG, Welsh JW. PDL1 Regulation by p53 via miR-34. J Natl Cancer Inst 108(1), 1/2016. e-Pub 11/17/2015. PMCID: PMC4862407.

Rebecca Howell Rebecca M. Howell, PhD, DABR, FAAPM
Associate Professor, Director Late Effects Group
MD Anderson Cancer Center
Radiation Physics, Section of Outreach Physics
Email:
rhowell@mdanderson.org


Rebecca M. Howell, PhD, is a tenured Associate Professor at The University of Texas MD Anderson Cancer Center and a Fellow of the American Association of Physicists in Medicine (AAPM). She received her MS (2001) and PhD (2005) from the University of Texas Health Science Center San Antonio. Dr. Howell is certified by the American Board of Radiology and has over 15 years of clinical experience. She has published 60 peer-reviewed papers and is/has been Principal and Co-investigator on several extramurally funded research grants and service agreements. Her research focuses on out-of-field dose and late effects of radiation therapy. She is recognized for her expertise in neutron dosimetry for both photon and proton therapy. She is Director of the Late Effects group at MD Anderson, which does retrospective dose reconstructions for numerous late effects studies for several large national and international cohorts including Childhood Cancer Survivor Study, St. Jude Life, Adult Life after Childhood Cancer in Scandinavia, and the Late Effects of Childhood Cancer task force of the Dutch Childhood Oncology Group. Dr. Howell was member of AAPM Task Group 158, which recently published (08/2017) “Measurement and calculation of doses outside the treated volume from external-beam radiation therapy”; as a member of TG-158, Dr. Howell provided expertise on secondary neutrons in photon and proton radiation therapy. Dr. Howell is also the Director of the Radiation Dosimetry Service, which provides independent peer review of beam output for over 2000 institutions in the United States and 150 institutions in other countries.

Selected Publications on Secondary Neutrons and Late Effects of Radiotherapy

  1. Giebeler A, Newhauser WD, Amos RA, Mahajan A, Homann K, Howell RM. Standardized treatment planning methodology for passively scattered proton craniospinal irradiation. Radiat Oncol 8:32, 2013. e-Pub 2/2013. PMCID: PMC3606426.
  2. Pérez-Andújar A, Newhauser WD, Taddei PJ, Mahajan A, Howell RM. The predicted relative risk of premature ovarian failure for three radiotherapy modalities in a girl receiving craniospinal irradiation. Phys Med Biol 58(10):3107-23, 5/2013. e-Pub 4/2013. PMID: 23603657.
  3. Zhang R, Howell R, Homann K, Giebeler A, Taddei P, Mahajan A, Newhauser W. Predicted risks of radiogenic cardiac toxicity in two pediatric patients undergoing photon or proton radiotherapy. Radiat Oncol 8(1):184, 7/2013.
  4. Howell RM, Burgett EA. Secondary neutron spectrum from 250-MeV passively scattered proton therapy: measurement with an extended-range Bonner sphere system. Med Phys 41(9):092104, 9/2014. PMCID: PMC4149696.
  5. Zhang R, Howell RM, Taddei PJ, Giebeler A, Mahajan A, Newhauser WD. A comparative study on the risks of radiogenic second cancers and cardiac mortality in a set of pediatric medulloblastoma patients treated with photon or proton craniospinal irradiation. Radiother Oncol 113(1):84-8, 10/2014. e-Pub 8/2014. PMCID: PMC4256116.
  6. Howell RM, Burgett EA, Isaacs D, Price Hedrick SG, Reilly MP, Rankine LJ, Grantham KK, Perkins S, Klein EE. Measured Neutron Spectra and Dose Equivalents From a Mevion Single-Room, Passively Scattered Proton System Used for Craniospinal Irradiation. Int J Radiat Oncol Biol Phys 95(1):249-57, 5/2016. e-Pub 12/2015. PMID: 27084645.
  7. Turcotte LM, Liu Q, Yasui Y, Arnold MA, Hammond S, Howell RM, Smith SA, Weathers RE, Henderson TO, Gibson TM, Leisenring W, Armstrong GT, Robison LL, Neglia JP. Temporal Trends in Treatment and Subsequent Neoplasm Risk Among 5-Year Survivors of Childhood Cancer, 1970-2015. JAMA 317(8):814-824, 2/2017. PMID: 28245323.
  8. Shaitelman SF, Howell RM, Smith BD. Effects of Smoking on Late Toxicity From Breast Radiation. J Clin Oncol: JCO2017722660. e-Pub 3/2017. PMID: 28319432.
  9. Moskowitz CS, Chou JF, Sklar CA, Barnea D, Ronckers CM, Friedman DN, Neglia JP, Turcotte L, Howell RM, Henderson TO, Armstrong GT, Leisenring WM, Robison LL, van Leeuwen FE, Pike MC, Oeffinger KC. Radiation-associated breast cancer and gonadal hormone exposure: a report from the Childhood Cancer Survivor Study. British Journal of Cancer, 2017.
  10. Kry SF, Bednarz B, Howell RM, Daur L, Followill D, Klein E, Paganetti H, Wong B, Wuu CS, Xu GX. AAPM TG 158: Measurement and calculation of doses outside the treated volume from external-beam radiation therapy. Med Phys Accepted Author Manuscript. doi:10.1002/mp.12462.

Constantine Mantz, MD Constantine A. Mantz, MD
Chief Medical Officer
21st Century Oncology
Email:
constantine.mantz@21co.com



Constantine Mantz, MD, serves as Chief Medical Officer for 21st Century Oncology. During the course of his career, he has been involved in numerous radiation therapy research projects, published professional journal articles and presented abstracts, poster sessions and lectures at national meetings concerning cancer treatment. Dr. Mantz has a special interest in the study and treatment of prostate cancer.

Recent Publications

  1. Baumann B. C., Bosch W. R., Bahl A., Birtle A. J., Breau R. H., Challapalli A., Chang A. J., Choudhury A., Daneshmand S., El-Gayed A., Feldman A., Finkelstein S. E., Guzzo T. J., Hilman S., Jani A., Malkowicz S. B., Mantz C. A., Master V., Mitra A. V., Murthy V., Porten S. P., Richaud P. M., Sargos P., Efstathiou J. A., Eapen L. J., Christodouleas J. P. Development and Validation of Consensus Contouring Guidelines for Adjuvant Radiation Therapy for Bladder Cancer After Radical Cystectomy. Int J Radiat Oncol Biol Phys. 2016
  2. Jae Y. Lee, Stephanie Daignault-Newton, Gerard Heath, Sarah Scarlett, Martin G. Sanda, Peter Chang, Meredith M. Regan, Jeff M. Michalski, Howard M. Sandler, Felix Y. Feng, Deborah A. Kuban, Anthony L. Zietman, Jay P. Ciezki, Irving D. Kaplan, Catrina Crociani, William P. McLaughlin, Constantine A. Mantz, Steven E. Finkelstein, Simeng Suy, Sean P. Collins, Olatz Garin, Montserrat Ferrer, Daniel A. Hamstra, Daniel E. Spratt. Multinational Prospective Study of Patient-Reported Outcomes After Prostate Radiation Therapy: Detailed Assessment of Rectal Bleeding. Int J Radiat Oncol Biol Phys. 2016

Reinhold Schulte, MD Reinhard W.M. Schulte, MD
Radiation Oncologist
Loma Linda University Medical Center
Email:
rschulte@llu.edu



Reinhard Schulte, MD was trained as a physicist and radiation oncologist with board certifications in radiology and radiation oncology in Germany as well as in the United States. He has more than 25 years of clinical and research experience in proton therapy, which he gained at the Proton Therapy Center at Loma Linda University Medical Center (LLUMC), He came to Loma Linda in 1990 as a postdoctoral fellow of the Deutsche Forschungsgemeinschaft - DFG (German Research Foundation) and 4 years later joined the staff of the Radiation Medicine Department. His first clinical project in proton therapy was the transfer of the former LBNL-UCSF-Stanford University helium ion radiosurgery program for arteriovenous malformations LLUMC. Since 2013, he is full Professor in the Division of Biomedical Engineering Sciences, at Loma Linda University Health. Dr. Schulte has pioneered major advancement in proton therapy technology including the development of nanodosimetry and proton computed tomography. From 2015-2017 he served as one of three PIs at the University of California San Francisco on a planning grant for particle therapy from the U.S. National Cancer Institute.

Recent Publications

  1. A. Berrington de Gonzalez, B. Vikram, J. C. Buchsbaum, F. de Vathaire, W. Dörr, D. Hass-Kogan, J. A. Langendijk, A. Mahajan, W. Newhauser, A. Ottolenghi, C. Ronckers, R. Schulte, L. Walsh, T. I. Yock, R. A. Kleinerman, A Clarion Call for Large-Scale Collaborative Studies of Pediatric Proton Therapy. Int. J. Radiat. Oncol. Biol. Phys. 98, 80-81, 2017.
  2. S Penfold, R Zalas, M Casiraghi, M Brooke, Y Censor, R Schulte. Sparsity constrained split feasibility for dose-volume constraints in inverse planning of intensity-modulated photon or proton therapy. Physics in Medicine and Biology, 62 (9), 3599-3618, 2017.
  3. V Giacometti, S Guatelli, M Bazalova-Carter, AB Rosenfeld, RW Schulte. Development of a high resolution voxelised head phantom for medical physics applications. Physica Medica;33:182-188, 2017.
  4. V Giacometti, VA Bashkirov, P Piersimoni, S Guatelli, TE Plautz H F‐W Sadrozinski, R P Johnson, A Zatserklyaniy, T Tessonnier, K Parodi, A B Rosenfeld, R W Schulte. Software platform for simulation of a prototype proton CT scanner, Medical Physics, 44 (3), 1002-1016, 2017. (Editor’s choice)
  5. P Piersimoni, J Ramos‐Méndez, T Geoghegan, VA Bashkirov, RW Schulte, BA Faddegon. The effect of beam purity and scanner complexity on proton CT accuracy. Medical Physics, 44(1):284-298, 2017.

Supporter/Exhibitor

PTCOG-NA 2017 Conference support is a great way to put your company and brand in front of industry leaders and experts while demonstrating your commitment to the field of particle therapy.

You can choose from several support levels that will provide the most value for your company:

  • Diamond
  • Platinum
  • Gold
  • Silver
  • Exhibitor

Our support packages offer your company high visibility and brand name recognition throughout the conference.

The Diamond and Platinum support levels include an opportunity to offer a 30-minute industry presentation during the lunch hour on either October 23rd or 24th.

Industry presentations will be assigned on a first come, first served basis. The sponsoring organization is responsible for any additional expenses such as audio visual.

Please click here for the Supporting Prospectus.